CCR2 and Patent ductus arteriosus: We then compared iKras* samples and iKras* p53* samples, reflecting early and late stages of PDA progression, and observed increased expression in Chil-TAM and Cq-TAM makers in the infiltrating macrophages, along with a loss of CCR2-TAM markers in advanced lesions (Figs 5G and S5F).